Agilent Technologies announced the launch of Agilent Advanced Therapeutics, a unified contract development and manufacturing organization (CDMO) solution that combines the company’s newly acquired BIOVECTRA in Canada with its existing Nucleic Acid Solutions facility in Colorado. The platform offers a full suite of services, including oligonucleotides, microbial fermentation, complex and synthetic chemistry, bioreagents, highly potent active pharmaceutical ingredients (APIs), and cell line development, enabling a single partner to support clients from discovery through commercial scale.
The launch represents a strategic expansion into the high‑margin CDMO market, which is growing as pharmaceutical and biotechnology companies outsource increasingly complex manufacturing. By integrating BIOVECTRA’s biologics expertise—particularly in highly potent APIs, pDNA, mRNA, and LNP formulation—with Agilent’s nucleic acid capabilities, the company can provide end‑to‑end solutions that reduce customer lead times and lower total cost of ownership.
Agilent completed the $925 million acquisition of BIOVECTRA on September 20, 2024, and the company expects a double‑digit return on invested capital by year five. The new CDMO platform is positioned to contribute significantly to Agilent’s revenue mix, complementing its long‑standing analytical instrument and consumables businesses and reinforcing the company’s long‑term growth strategy.
Padraig McDonnell, Agilent President and CEO, said, "The Agilent Advanced Therapeutics solution strengthens our ability to support our customers and reinforces our long‑term commitment to growth, investment, and leadership in this space." He added, "For our customers, this means a more integrated experience, deeper technical partnership and a trusted team that understands what it takes to bring life‑changing therapies to patients." Simon May, president of Agilent's Life Sciences and Diagnostics Markets Group, commented, "This launch reflects the combined excellence of our teams and our commitment to advancing the next generation of therapies. We are excited to bring our unified Agilent Advanced Therapeutics capabilities to partners around the world."
The integrated solution positions Agilent to compete more effectively with established CDMOs by offering a broader range of services under a single umbrella. The company’s focus on high‑margin, end‑to‑end manufacturing capabilities is expected to deepen customer relationships, capture a larger share of the growing CDMO market, and strengthen Agilent’s competitive position and long‑term growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.